Peptide Dosing Chart

50 commonly discussed peptides, with a reconstitution calculator. Select a row to see its details.

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.

		Typical dose			Reviews / Q&A	Route
Ozempic, Wegovy	Weight & metabolic	0.25 mg rising to 2.4 mg	Weekly	≈ 36–343 mcg/day	Add first	Subcutaneous	FDA-approved
Mounjaro, Zepbound	Weight & metabolic	2.5 mg rising to 5–15 mg	Weekly	≈ 0.36–2.1 mg/day	Add first	Subcutaneous	FDA-approved
LY3437943	Weight & metabolic	1–12 mg	Weekly	≈ 0.14–1.7 mg/day	Add first	Subcutaneous	Clinical trials
Saxenda, Victoza	Weight & metabolic	0.6 mg rising to 3 mg	Daily	0.6–3 mg/day	Add first	Subcutaneous	FDA-approved
part of CagriSema	Weight & metabolic	0.25 mg rising to 2.4 mg	Weekly	≈ 36–343 mcg/day	Add first	Subcutaneous	Clinical trials
BI 456906	Weight & metabolic	0.6–6 mg	Weekly	≈ 86–857 mcg/day	Add first	Subcutaneous	Clinical trials
IBI362	Weight & metabolic	4 mg or 6 mg	Weekly	≈ 0.57–0.86 mg/day	Add first	Subcutaneous	Approved outside US
Imcivree	Weight & metabolic	2 mg rising to 3 mg	Daily	2–3 mg/day	Add first	Subcutaneous	FDA-approved
Symlin	Weight & metabolic	15–120 mcg per meal	Daily, with each meal	≈ 45–360 mcg/day	Add first	Subcutaneous	FDA-approved
hGH fragment 177-191 analog	Weight & metabolic	300 mcg	Daily	300 mcg/day	Add first	Subcutaneous	Not approved
Frag 176-191	Weight & metabolic	250–500 mcg	Daily	250–500 mcg/day	Add first	Subcutaneous	Not approved
NS2330	Weight & metabolic	0.25–0.5 mg	Daily	0.25–0.5 mg/day	Add first	Oral	Clinical trials
NNMT inhibitor	Weight & metabolic	50–150 mg	Daily	50–150 mg/day	Add first	Oral	Not approved
Mod GRF 1-29	Growth hormone	100 mcg	Daily, 1–3 times	100–300 mcg/day	Add first	Subcutaneous	Not approved
DAC:GRF	Growth hormone	1–2 mg	Weekly	≈ 143–286 mcg/day	Add first	Subcutaneous	Not approved
Advertisement Advertise here
	Growth hormone	100–300 mcg	Daily, 1–3 times	100–900 mcg/day	Add first	Subcutaneous	Not approved
Geref	Growth hormone	200–500 mcg	Daily, at bedtime	200–500 mcg/day	Add first	Subcutaneous	Not approved
Egrifta SV, Egrifta WR	Growth hormone	1.4 mg (SV) or 1.28 mg (WR)	Daily	1.28–1.4 mg/day	Add first	Subcutaneous	FDA-approved
pralmorelin	Growth hormone	100–300 mcg	Daily, 1–3 times	100–900 mcg/day	Add first	Subcutaneous	Not approved
	Growth hormone	100–300 mcg	Daily, 1–3 times	100–900 mcg/day	Add first	Subcutaneous	Not approved
examorelin	Growth hormone	100–200 mcg	Daily, 1–3 times	100–600 mcg/day	Add first	Subcutaneous	Not approved
ibutamoren	Growth hormone	10–25 mg	Daily	10–25 mg/day	Add first	Oral	Clinical trials
long R3 IGF-1	Growth hormone	20–50 mcg	Daily	20–50 mcg/day	Add first	Subcutaneous or intramuscular	Not approved
body protection compound	Healing & recovery	250–500 mcg	Daily	250–500 mcg/day	Add first	Subcutaneous or oral	Not approved
thymosin beta-4 fragment	Healing & recovery	2–5 mg per week	Twice weekly	≈ 0.29–0.71 mg/day	Add first	Subcutaneous	Not approved
copper peptide	Healing & recovery	1–2 mg	Daily	1–2 mg/day	Add first	Subcutaneous or topical	Not approved
alpha-MSH fragment	Healing & recovery	200–500 mcg	Daily	200–500 mcg/day	Add first	Subcutaneous or oral	Not approved
cathelicidin	Healing & recovery	50–100 mcg	Daily	50–100 mcg/day	Add first	Subcutaneous	Not approved
cibinetide	Healing & recovery	4 mg	Daily	4 mg/day	Add first	Subcutaneous	Clinical trials
vasoactive intestinal peptide, aviptadil	Healing & recovery	50 mcg per spray	Daily, up to 4 times	up to 200 mcg/day	Add first	Intranasal	Clinical trials
Advertisement Advertise here
	Cognitive & sleep	200–900 mcg per day	Daily, 2–3 times	200–900 mcg/day	Add first	Intranasal	Approved outside US
	Cognitive & sleep	300–900 mcg per day	Daily, 2–3 times	300–900 mcg/day	Add first	Intranasal	Approved outside US
PNB-0408	Cognitive & sleep	8–20 mg	Daily	8–20 mg/day	Add first	Oral	Not approved
delta sleep-inducing peptide	Cognitive & sleep	100–250 mcg	Daily, at bedtime	100–250 mcg/day	Add first	Subcutaneous	Not approved
	Cognitive & sleep	5–30 mL	Daily, in short courses	5–30 mL/day	Add first	Intramuscular or intravenous	Approved outside US
	Cognitive & sleep	10 mg	Daily, in short courses	10 mg/day	Add first	Intramuscular	Approved outside US
epithalon	Longevity & immune	5–10 mg	Daily, in short courses	5–10 mg/day during a course	Add first	Subcutaneous	Not approved
thymalfasin, Zadaxin	Longevity & immune	1.6 mg	Twice weekly	≈ 0.46 mg/day	Add first	Subcutaneous	Approved outside US
	Longevity & immune	5–10 mg	2–3 times weekly	≈ 1.4–4.3 mg/day	Add first	Subcutaneous	Not approved
elamipretide, Forzinity	Longevity & immune	40 mg	Daily	40 mg/day	Add first	Subcutaneous	FDA-approved
nicotinamide adenine dinucleotide	Longevity & immune	50–200 mg	Daily to 2–3 times weekly	up to 200 mg/day	Add first	Subcutaneous	Not approved
	Longevity & immune	5–20 mg	Daily, in short courses	5–20 mg/day during a course	Add first	Intramuscular	Approved outside US
bremelanotide, Vyleesi	Sexual & hormonal	1.75 mg	As needed	Not a daily drug	Add first	Subcutaneous	FDA-approved
MT-2	Sexual & hormonal	250–500 mcg	Daily, then 1–2 times weekly	250–500 mcg/day	Add first	Subcutaneous	Not approved
afamelanotide, Scenesse	Sexual & hormonal	16 mg implant	Every 2 months	≈ 0.27 mg/day	Add first	Subcutaneous implant	FDA-approved
Advertisement Advertise here
	Sexual & hormonal	100–200 mcg	As needed	100–200 mcg/day	Add first	Subcutaneous	Clinical trials
Pitocin (injection)	Sexual & hormonal	10–40 IU per dose	Daily, 1–2 times	Measured in IU, not mcg	Add first	Intranasal	FDA-approved
GnRH	Sexual & hormonal	100 mcg	2–3 times weekly	≈ 29–100 mcg/day	Add first	Subcutaneous	Not approved
Forteo	Bone	20 mcg	Daily	20 mcg/day	Add first	Subcutaneous	FDA-approved
Tymlos	Bone	80 mcg	Daily	80 mcg/day	Add first	Subcutaneous	FDA-approved

Showing 50 of 50

Semaglutide

Also known as: Ozempic, Wegovy

FDA-approved

Category: Weight & metabolic
Typical dose: 0.25 mg rising to 2.4 mg
How often: Weekly
Schedule: Once weekly. Start at 0.25 mg and step up every 4 weeks: 0.5, 1, 1.7, then 2.4 mg.
Daily equivalent: ≈ 36–343 mcg/day
Reviews / Q&A: Add first
Route: Subcutaneous
Duration: Ongoing

Wegovy schedule shown. A 7.2 mg weekly dose (Wegovy HD) was approved in March 2026 for adults who have tolerated 2.4 mg for at least 4 weeks. Ozempic for diabetes is maintained at 0.5–2 mg weekly. Brand products are prefilled pens; the calculator applies to vials only. Boxed warning for thyroid C-cell tumors.

Open the full Semaglutide page

Reconstitution calculator

Peptide in vial (mg)

Water added (mL)

Dose per injection

Syringe (U-100 insulin)

Draw to 10 units

0.1 mL on a 100-unit syringe

2.5 mg/mLconcentration

25 mcgper unit mark

20doses per vial

“Daily equivalent” spreads weekly or intermittent doses evenly across seven days so entries can be compared; it is not a suggestion to dose daily. Vial sizes pre-filled in the calculator are common examples. Always enter the amount printed on your own vial. Doses for the FDA-approved entries were checked against US prescribing information in October 2026. Labels change, so confirm against the current one.